Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG3667 in Healthy Male Subjects
NCT04976270Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cadefrecitinib in psoriasis, dermatomyositis (DM) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Galapagos NV. Primary endpoint: Treatment-Emergent Adverse Events. Started Jul 2021; status: completed.
02
Drugs
cadefrecitinib
03
Conditions
psoriasisdermatomyositis (DM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04976270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976270.